Engineering the medicines
of tomorrow

You are here

The future of healthcare will be built on truly differentiated therapies that can make a real difference in how diseases are treated and transform the way patients can live their lives. At MorphoSys, all disciplines and teams work hand in hand to facilitate the advancement of such novel compounds, from their discovery through to clinical development.

We believe that successful drug development is not a matter of chance, but based on a profound understanding of disease biology, excellent technologies and extensive experience in the selection, characterization and development of therapeutic candidates.

Morphosys´s technologies and the expertise of its employees in the development of biologics support the search for drug candidates with unique properties.

With our skills, knowledge and expertise we have built a comprehensive portfolio of promising drug candidates. Technologies are an essential part of the development process of a compound. Smarter tools provide faster, more flexible and, ultimately, better-quality access to drug candidates. Our technologies are setting the standard for how antibodies have been made and will be developed in the future. They provide rapid and direct access to fully human antibodies for use as research tools, diagnostics and therapeutics.


Main research areas

MorphoSys is constantly striving to improve its drug development capabilities, to consolidate its disease expertise and to strengthen the company’s technology suite. Our research and development activities currently focus on cancer, both hematological malignancies and solid tumors, as well as inflammatory and autoimmune diseases.

Cancer

Cancer is not a single disease, but includes a large number of heterogeneous indications leading to a wide range of unmet medical needs. Standard treatments for the various forms of cancer include surgery, chemotherapy, radiation therapy and hormone treatment. However, new biological products hold a huge promise for changing treatment paradigms. Drugs such as therapeutic antibodies may allow for highly specific targeting of cancer cells or signaling molecules in order to potentially offer a different safety profile.

Tafasitamab
(MOR208)

Visit

Felzartamab
(MOR202)

Visit

Immuno-oncology: a new paradigm in the fight against cancer

Immuno-oncology is one of the most exciting areas of research in the biopharmaceutical industry. With the development of therapies that modulate the immune system´s natural ability to fight tumors, researchers are striving to reach major breakthroughs that will overcome the shortcomings of chemotherapy and radiation treatments. Antibody-based immuno-oncologic therapies have shown promise with the potential to provide additional treatment options for a broad range of cancer patients.

Modern immune therapies seek to enhance the immune response against the tumor and block evasion strategies of cancer cells. Multiple development steps are needed to generate potent anti-tumor immune responses. MorphoSys has already worked on a range of immune checkpoint targets and we are leveraging our proprietary Ylanthia antibody library and other technology platforms to generate antibodies that target specific immune checkpoints.

Epigenetics

Constellation Pharmaceuticals – a MorphoSys company - is a pioneer in the discovery and development of novel therapeutics that target the writer, reader and eraser classes of epigenetic regulators and modulate gene expression in a highly selective manner. Constellation’s research team has demonstrated that these distinct classes of epigenetic regulators are broadly druggable and that selective reprogramming of gene expression is a promising therapeutic approach not only to induce cancer cell killing but also to enhance anti-tumor immunity.

Constellation Pharmaceuticals’ integrated epigenetics platform includes a deep understanding of the biological context in which epigenetic regulators operate, the development of small-molecule product candidates that selectively modulate their activity and the design of clinical development programs supported by novel biomarker strategies.

Find more information on Constellation‘s scientific approach here.

Inflammatory and autoimmune diseases

Both autoimmune and inflammatory diseases arise through uncharacteristic reactions of the human immune system. In autoimmunity, the patient's immune system is activated against the body's own proteins. In chronic inflammatory diseases, neutrophils and other leukocytes are constitutively recruited by cytokines and chemokines, leading to tissue damage. Inflammatory disorders include conditions such as rheumatoid arthritis (RA), multiple sclerosis (MS), asthma, chronic obstructive pulmonary disease (COPD), psoriasis and inflammatory bowel disease.

Around 1% of the global population is thought to be affected by rheumatoid arthritis, which makes it the largest single market in the area of inflammatory diseases. Additionally, certain bone-related indications involve inflammatory processes. Inflammatory and autoimmune diseases represent a major challenge for millions of patients.

Antibodies that target GPCRs

The G protein-coupled receptor (GPCR) superfamily is the largest and single most important family of drug targets (~800 members) in the human body. These proteins are active in just about every organ system and present a wide range of opportunities as therapeutic targets in areas including cancer, cardiac dysfunction, diabetes, central nervous system disorders, obesity, inflammation and pain.

Over 300 family members are considered as relevant targets for drug discovery. However, due to technical challenges in targeting the very small, partially hidden extracellular protein region which is accessible to antibodies, GPCRs have been largely intractable to therapeutic antibody development so far.

MorphoSys combines its expertise and techniques to drive antibodies to the small extracellular GPCR surface.